微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 56.01% | 1.69% | 2.64% | 59/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 54.57% | -2.83% | -5.87% | 68/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 57.97% | -2.91% | 11.73% | 60/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 51.89% | -8.28% | -5.8% | 70/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 55.08% | -3.69% | -1.92% | 66/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 56.16% | -2.74% | -5.95% | 61/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 59.71% | -3.98% | 5.55% | 51/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 56.57% | -3.77% | -1.08% | 63/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 57.19% | 0.25% | -0.96% | 63/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 57.75% | 4.26% | -7.14% | 59/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 62.19% | -1.12% | 5.78% | 45/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 58.79% | 4.99% | 3.05% | 58/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 57.05% | 0.93% | 3% | 64/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 55.39% | 0.86% | -11.93% | 66/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 62.89% | 14.73% | 12.32% | 45/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 55.99% | 0.96% | -0.93% | 71/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 56.52% | -1.01% | 2.93% | 65/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 54.91% | -5.17% | 0.17% | 70/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 54.82% | -7.77% | -1.16% | 70/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 55.46% | -3.11% | -2.86% | 75/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 57.1% | -3.86% | -1.4% | 59/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 57.91% | -3.13% | -2.58% | 63/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 59.44% | 1.42% | 3.83% | 50/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 57.24% | -0.33% | -3.62% | 64/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 59.39% | 4.45% | -0.65% | 51/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 59.78% | 4.67% | 2% | 51/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 58.61% | 4.08% | 2.05% | 48/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 57.43% | 0.04% | 1.01% | 64/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 56.86% | -2.34% | -0.44% | 53/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 57.11% | -0.78% | 1.43% | 55/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 56.31% | 1.3% | -1.92% | 51/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 57.41% | 12.4% | -1.39% | 60/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 58.22% | 20.01% | 1.15% | 45/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 57.56% | 24.82% | 3.55% | 45/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 55.58% | 2% | 8.82% | 48/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 51.08% | 22.96% | 5.29% | 62/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 48.51% | 2% | 5.2% | 47/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 46.11% | 23.59% | 11% | 52/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 41.54% | 12.62% | 12.62% | 65/159 | 48.17% | 退市金泰 | 95.93% | 行业排名> |